Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.
1. The ORL1 agonists nociceptin and Ro 64-6198 were compared in their ability to modify spontaneous locomotor activity in male NMRI mice not habituated to the test environment. 2. Higher doses of nociceptin (>5 nmol i.c.v.) reduced whereas lower doses (<1 nmol i.c.v.) stimulated locomotor activity. Both effects were blocked by the putative ORL1 antagonists [NPhe1]nociceptin(1-13)NH2 (10 nmol i.c.v.) and UFP101 (10 nmol, i.c.v.). The effects were also blocked by naloxone benzoylhydrazone (1 mg x kg(-1) s.c.), but not by the nonselective opioid antagonist naloxone (1 mg x kg(-1) s.c.). 3 In contrast to nociceptin, the synthetic ORL1 agonist Ro 64-6198 (0.01-1.0 mg x kg(-1) i.p.) produced monophasic inhibition of locomotor activity, which was insensitive to the treatment with [NPhe1]nociceptin(1-13)NH2 or naloxone benzoylhydrazone. Treatment with UFP101 abolished the locomotor inhibition induced by Ro 64-6198 (1.0 mg x kg(-1)), whereas naloxone (1.0 mg x kg(-1), s.c.) further increased the locomotor-inhibitory effects. 4. Naloxone benzoylhydrazone (0.3; 1.0 and 3.0 mg x kg(-1) s.c.) increased locomotor activity, although the effect was statistically significant only with the highest dose used. 5. Pretreatment with the tyrosine hydroxylase inhibitor H44-68 totally eliminated the motor-stimulatory effects of low doses of nociceptin, probably via dopamine depletion. 6. The results suggest that nociceptin stimulates locomotor activity at low doses if dopamine activity is intact. High doses of nociceptin and all the tested doses of Ro 64-6198 seem to interact with a functionally different subset of ORL1 receptors. In addition, the effects of Ro 64-6198 are modulated by tonic opioid receptor activity.
Kuzmin
Alexander
A
Department of Neuroscience, Karolinska Institutet, Stockholm S-171 77, Sweden. alexander.kuzmin@neuro.ki.se
Sandin
Johan
J
Terenius
Lars
L
Ogren
Sven Ove
SO
D000818:Animals; D002555:Cerebrospinal Fluid / Q000737:chemistry / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004357:Drug Synergism; D007093:Imidazoles / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D008297:Male; D008722:Methods; D008781:Methyltyrosines / Q000008:administration & dosage / Q000493:pharmacokinetics; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D009270:Naloxone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D009292:Narcotic Antagonists; D018847:Opioid Peptides / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000493:pharmacokinetics; D011957:Receptors, Opioid / Q000008:administration & dosage / Q000502:physiology*; D013141:Spiro Compounds / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D014446:Tyrosine 3-Monooxygenase / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D000094942:Nociceptin Receptor; D000097629:Nociceptin
D004338:Drug Combinations; D007093:Imidazoles; D008781:Methyltyrosines; D009270:Naloxone; D009292:Narcotic Antagonists; D018847:Opioid Peptides; D011957:Receptors, Opioid; D013141:Spiro Compounds; D014446:Tyrosine 3-Monooxygenase; D000094942:Nociceptin Receptor; D000097629:Nociceptin; C479838:(Nphe(1),Arg(14),Lys(15))N-OFQ NH(2); C408068:Ro 64-6198; C058380:naloxone benzoylhydrazone; C022260:alpha-methyltyrosine methyl ester; C000722287:Oprl1 protein, mouse